Variation in event rates in trials of patients with type 2 diabetes

JAMA

Volumn 302, Issue 15, 2009, Pages 1698-1700

  Psaty, Bruce M ^a,c   Prentice, Ross L ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIDIABETIC AGENT;

BLOOD PRESSURE; BODY MASS; DIABETIC PATIENT; HEART INFARCTION; HUMAN; INCIDENCE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RISK FACTOR; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; REPRODUCIBILITY; RISK ASSESSMENT; STANDARD; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70350702740     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1497     Document Type: Note

References (10)

1. Prentice RL. Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst. 2009;101(4):216-217.
2. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
3. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
4. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
5. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
6. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROACTIVE Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet. 2005;366(9493):1279-1289.
7. Atherosclerosis Risk in Communities (ARIC). ARIC incidence tables. http://www.cscc.unc.edu/aric/. Accessed July 7, 2006.
8. Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol. 2002;155(1):38-47.
9. Davis BR, Whelton PK; ALLHAT Collaborative Research Group. Benazepril plus amlodipine or hydrochlorothiazide for hypertension. N Engl J Med. 2009;360:1148-1149.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.